Beatriz M. Carreno, PhD
Research Professor of Pathology and Laboratory Medicine

- Member, University of Pennsylvania, Parker Institute for Cancer Immunotherapy
- Member, University of Pennsylvania, Center for Cellular Immunotherapies
- Member, University of Pennsylvania, Institute for Immunology
Department: Pathology and Laboratory Medicine
Graduate Group Affiliations
Contact Information
PCAM South Tower, 8th Floor
3400 Civic Blvd
Philadelphia, PA 19104
Office: 215-573-7044
Lab Phone: 215-573-4931
Email: bcarreno@upenn.edu
I3H Keywords
- Tumor Microenvironment
- Systems Immunology and Genomics
Publications
Links
Education
-
BS
Universidad Simon Bolivar, Caracas, Venezuela, 1981 -
PhD (Microbiology)
Georgetown University School of Medicine, 1989
Post-Graduate Training
-
Visiting Postdoctoral Fellow, Neuro-immunology
NINDS, NIH , 1989 - 1991 -
Postdoctoral Research Associate, Genetics
Washington University School of Medicine, 1991 - 1995
Description of ITMAT Expertise
My research interests have centered on questions related to the generation and modulation of anti-tumor human T cell immunity and how these responses can be harnessed to develop better immune therapeutics. My laboratory develops methods for (1) identification of tumor antigens, (2) characterization of novel T cell receptors (TCR) and (3) development of novel TCR-T cell therapies. Our lab has well-documented experience in the identification and expansion of tumor (shared and neoantigen)-specific CD8+ T cells derived from cancer patients and the development of cellular immunotherapies.
Selected Publications
- Benton A., Liu J., Poussin M.A., Lang Goldgewicht A., Udawela M., Bear A.S., Wellhausen N., Carreno B.M., Smith P.M., Beasley M.D., Kiefel B.R., Powell D.J. Jr : Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy Cancer Cell 43(7) : 1365-1376.e5, Jul 2025 Notes: doi: 10.1016/j.ccell.2025.05.006. Epub 2025 Jun 5. PMID: 40480232
- Blanchard T., Faridi P., Xu C., Bear A.S., Rasool R.U., Huang G., Lim T.C.C., Ayala R., Gabunia K., Ji M., Posey A.D. Jr, Scholler J., Asangani I.A., Purcell A.W., Linette G.P., June C.H., Carreno B.M. : LOXHD1 is an oncofusion-regulated antigen of ewing sarcoma Sci Rep 15(1) : 13007, Apr 2025 Notes: doi: 10.1038/s41598-025-96877-9. PMID: 40234527 Free PMC article.
- Porazzi P., Nason S., Yang Z., Carturan A., Ghilardi G., Guruprasad P., Patel R.P., Tan M., Padmanabhan A.A., Lemoine J., Fardella E., Zhang Y., Pajarillo R., Chen L., Ugwuanyi O., Markowitz K., Delman D., Angelos M.G., Shestova O., Isshiki Y., Blanchard T., Béguelin W., Melnick A.M., Linette G.P., Beatty G.L., Carreno B.M., Cohen I.J., Paruzzo L., Schuster S.J., Ruella M. : EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models Cancer Cell 43(3) : 537-551.e7, Mar 2025 Notes: doi: 10.1016/j.ccell.2025.01.013. Epub 2025 Feb 20. PMID: 39983725
- Bear A.S., Nadler R.B., O'Hara M.H., Stanton K.L., Xu C., Saporito R.J., Rech A.J., Baroja M.L., Blanchard T., Elliott M.H., Ford M.J., Jones R., Patel S., Brennan A., O'Neil Z., Powell D.J. Jr, Vonderheide R.H., Linette G.P., Carreno B.M. : Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors J Clin Invest 134(21) : e175790, Sep 2024 Notes: doi: 10.1172/JCI175790. PMID: 39287991 Free PMC article. Clinical Trial.
- Patel, R.P., Ghilardi, G., Zhang, Y., Chiang, Y., Xie, W., Guruprasad, P., Kim, K., Chun, I., Angelos, M.G., Pajarillo, R., Hong, S., Lee, Y., Shestova, O., Shaw, C., Cohen, I., Gupta, A., Vu, T., Qian, D., Yang, S., Nimmagadda, A., Snook, A.E., Siciliano, N., Rotolo, A., Inamdar, A., Harris, J., Ugwuanyi, O., Wang, M., Carturan, A., Paruzzo, L., Chen, L., Ballard, H.J., Blanchard, T., Xu, C., Abdel-Mohsen, M., Gabunia, K., Wysocka, M., Linette, G.P., Carreno, B.M., Barrett, D.M., Teachey, D.T., Posey, A.D., Powell Jr., D.J., Sauter, C.T., Pileri, S., Pillai, V., Scholler, J., Rook, A.H., Schuster, S.J., Barta, S.K., Porazzi, P., Ruella, M. : CD5 deletion enhances the antitumor activity of adoptive T cell therapies Sci Immunol 9(97) : eadn6509, Jul 2024
- Patel R.P., Ghilardi G., Zhang Y., Chiang Y.H., Xie W., Guruprasad P., Kim K.H., Chun I., Angelos M.G., Pajarillo R., Hong S.J., Lee Y.G., Shestova O., Shaw C., Cohen I., Gupta A., Vu T., Qian D., Yang S., Nimmagadda A., Snook A.E., Siciliano N., Rotolo A., Inamdar A., Harris J., Ugwuanyi O., Wang M., Carturan A., Paruzzo L., Chen L., Ballard H.J., Blanchard T., Xu C., Abdel-Mohsen M., Gabunia K., Wysocka M., Linette G.P., Carreno B.M., Barrett D.M., Teachey D.T., Posey A.D., Powell D.J. Jr, Sauter C.T., Pileri S., Pillai V., Scholler J., Rook A.H., Schuster S.J., Barta S.K., Porazzi P., Ruella M. : CD5 deletion enhances the antitumor activity of adoptive T cell therapies Sci Immunol 9(97) : eadn6509, Jul 2024 Notes: doi: 10.1126/sciimmunol.adn6509. Epub 2024 Jul 19. PMID: 39028827 Free PMC article.
- Linette GP, Bear AS, Carreno BM : Facts and hopes in immunotherapy strategies targeting antigens derived from KRAS mutations Clin Cancer Res Jan 2024 Notes: doi: 10.1158/1078-0432.CCR-23-1212. Online ahead of print.
- Lee IK, Sharma N, Noguera-Ortega E, Liousia M, Baroja ML, Etersque JM, Pham J, Sarkar S, Carreno BM, Linette GP, Puré E, Albelda SM, Sellmyer MA. : A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy Mol Ther 31(12) : 3564-3578, Dec 2023
- Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R, Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, Stadtmauer EA. : Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy Blood Cancer Discov 4(2) : 118-133, Mar 2023
- Bear, A.S., Nadler, R.B., Scholler, J., Vonderheide, R.H., Linette, G.P., Carreno, B.M. : TCR1020 specific for KRAS G12V restricted to HLA-A*11:01 exhibits potent and precise antigen specificity for clinical development AACR- Targeting Ras, Philadelphia, PA Mar 2023 Notes: Oral Presentation